1. Health

Adenomyosis Drugs Market Foraying into Emerging Economies 2028

Disclaimer: This is a user generated content submitted by a member of the WriteUpCafe Community. The views and writings here reflect that of the author and not of WriteUpCafe. If you have any complaints regarding this post kindly report it to us.

The report Global Adenomyosis Drugs Market Growth 2021-2028” from Databridge Market Research includes data and information about market structure and size. The purpose of this research is to give market knowledge and strategic insights to assist in decision making, making informed investment decisions, and identifying potential growth opportunities.

Adenomyosis is a benign uterine disorder in which endometrial glands and stroma are pathologically demonstrated in the myometrium. Women affected by adenomyosis may present with abnormal uterine bleeding (AUB), dysmenorrhea, dyspareunia, or infertility, but one-third of them are asymptomatic. Over the years, adenomyosis has remained a histopathological diagnosis made after hysterectomy in perimenopausal women with heavy menstrual bleeding (HMB) or pelvic pain. However, adenomyosis has also become a condition identified in young fertile-age women over the last decade because of the recent advancements in imaging techniques, even though a shared definition and classification are still lacking. Despite the improvement of diagnostic tools, the awareness of the condition is still poor.

Download Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-adenomyosis-drugs-market

The Global Adenomyosis Drugs Market market report also indicates a narrowed decisive summary of the market. Along with this, multiple factors which have affected the advancement and improvement in a positive as well as negative manner are also studied in the report. On the contrary, the various factors which will be acting as the opportunities for the development and growth of the Global Adenomyosis Drugs Market market in the forecasted period are also mentioned.

Top Keyplayers in Global Adenomyosis Drugs Market Report:

Mayne Pharma Group Limited, Accord Healthcare, Tolmar Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, TerSera Therapeutics LLC, Ferring B.V., Lannett, Par Pharmaceutical (A Subsidiary of Endo International plc), Hikma Pharmaceuticals PLC, Context Therapeutics Inc., Viatris Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Zydus Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd, AbbVie Inc., Abbott, GlaxoSmithKline plc., Novartis AG, Amneal Pharmaceuticals LLC, Johnson & Johnson Services, Inc., Sanofi, Dr. Reddy's Laboratories Ltd., among others.

Feel Free To Ask Question Before Purchasing The Report @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-adenomyosis-drugs-market

Global Adenomyosis Drugs Market Regional Analysis

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Request for TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-adenomyosis-drugs-market

Drivers

  • High prevalence of adenomyosis disorders

Gynecologic disorders affect the female reproductive system. The most common symptoms of gynecologic disorders include pelvic pain, endometriosis, adenomyosis, abnormal vaginal bleeding, and breast pain and lumps, among others. The significance and severity of these symptoms often depend on age, as these symptoms may be related to hormonal changes that occur with aging.

With the increasing women population worldwide, the target population for female reproductive disorder has also increased. Adenomyosis, a gynecologic condition characterized by the presence of endometrial glands and stroma within the myometrium, can significantly reduce the lifestyle of an individual. Adenomyosis occurs in 8.8% to 61.5% of women undergoing hysterectomy, and rates vary widely by differences in diagnostic criteria and variations between and within pathologists. The prevalence is estimated to range from 20% to 34%, based on patients referred for pelvic imaging rather than the general population of women.

  • Advancement in diagnosis of adenomyosis

The development of imaging techniques, such as MRI and transvaginal ultrasonography (TVUS), has allowed clinicians to make a non-invasive diagnosis of adenomyosis in women also undergoing conservative treatments, identifying different phenotypes of the disease. After some attempts of histological classification, adenomyosis is classified into four subtypes according to MRI lesion localization in the inner or outer myometrium: intrinsic, extrinsic, intramural, and indeterminate. 

Opportunity

  • Increase demand for disease-specific drug treatment

According to pathogenic mechanisms, several medical hormonal and non-hormonal treatments are used off-label to manage pain and bleeding and to improve fertility outcomes. The use of GnRHa is indicated before fertility treatments to improve the chances of pregnancy in infertile women with adenomyosis, and the highest pregnancy rate is reported in those undergoing frozen embryo transfer after GnRHa pre-treatment. In contrast, the use of GnRHa for pain and bleeding should be considered only for short-term treatment because of menopausal effects. The levonorgestrel-releasing intrauterine system (LNG-IUS) is also an effective, reversible, and long-term treatment used successfully to treat adenomyosis. Results show that it reduces menstrual bleeding, pain, and uterine volume and has an overall satisfaction of 72%. However, new drugs, such as selective progesterone receptor modulators, aromatase inhibitors, valproic acid, and anti-platelet therapy, are under development for the treatment of adenomyosis.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-adenomyosis-drugs-market

About Data Bridge Market Research:                        

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

 

0

Login

Welcome to WriteUpCafe Community

Join our community to engage with fellow bloggers and increase the visibility of your blog.
Join WriteUpCafe